Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes

Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes

Specific myeloid-related and inositide-specific gene mutations can be linked to myelodysplastic syndromes (MDS) pathogenesis and therapy. Here, 44 higher-risk MDS patients were treated with azacitidine and lenalidomide and mutations analyses were performed at baseline and during the therapy. Results...

पूर्ण विवरण

ग्रंथसूची विवरण
मुख्य लेखकों:	Follo, M, Pellagatti, A, Armstrong, R, Ratti, S, Mongiorgi, S, De Fanti, S, Bochicchio, M, Russo, D, Gobbi, M, Miglino, M, Parisi, S, Martinelli, G, Cavo, M, Luiselli, D, McCubrey, J, Suh, P, Manzoli, L, Boultwood, J, Finelli, C, Cocco, L
स्वरूप:	Journal article
भाषा:	English
प्रकाशित:	Springer Nature 2019

समान संसाधन

Recent advances in MDS mutation landscape: splicing and signalling
द्वारा: Follo, MY, और अन्य
प्रकाशित: (2019)

Phospholipase C beta1 (PI-PLCbeta1)/Cyclin D3/protein kinase C (PKC) alpha signaling modulation during iron-induced oxidative stress in myelodysplastic syndromes (MDS)
द्वारा: Cappellini, A, और अन्य
प्रकाशित: (2020)

Lenalidomide selectively inhibits in vitro growth of the malignant clone in myelodysplastic syndrome (MDS) patients with 5q deletion.
द्वारा: Jadersten, M, और अन्य
प्रकाशित: (2005)

MDS-197: Magrolimab + azacitidine versus azacitidine + placebo in untreated higher-risk (HR) myelodysplastic syndromes (MDS): the phase 3, randomized, ENHANCE study
द्वारा: Garcia-Manero, G, और अन्य
प्रकाशित: (2021)

Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia
द्वारा: Dickinson, M, और अन्य
प्रकाशित: (2018)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndrome (MDS): the phase 3, randomized, ENHANCE study
द्वारा: Garcia-Manero, G, और अन्य
प्रकाशित: (2021)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndromes (MDS): the Phase 3, randomized, ENHANCE Study
द्वारा: Garcia-Manero, G, और अन्य
प्रकाशित: (2021)

MDS-482 Impact of magrolimab in combination with azacitidine on red blood cells (RBCs) in patients with higher-risk myelodysplastic syndromes (HR MDS)
द्वारा: Chen, J, और अन्य
प्रकाशित: (2022)

TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients.
द्वारा: Caceres, G, और अन्य
प्रकाशित: (2013)

MDS-445 Magrolimab in combination with azacitidine for patients with untreated higher-risk myelodysplastic syndromes (HR MDS): 5F9005 phase 1b study results
द्वारा: Sallman, D, और अन्य
प्रकाशित: (2022)

Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib–lenalidomide–dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study
द्वारा: Lee, HC, और अन्य
प्रकाशित: (2024)

Generalized GM-MDS: Polynomial Codes Are Higher Order MDS
द्वारा: Brakensiek, Joshua, और अन्य
प्रकाशित: (2024)

Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide
द्वारा: Jan, Max, और अन्य
प्रकाशित: (2021)

INVESTIGATION OF THE MOLECULAR BASIS OF LENALIDOMIDE TREATMENT IN LYMPHOMA CELL LINES
द्वारा: Ballabio, E, और अन्य
प्रकाशित: (2010)

The weights in MDS codes
द्वारा: Ezerman, Martianus Frederic, और अन्य
प्रकाशित: (2019)

Lenalidomide up-regulates SPARC and inhibits in vitro growth of the malignant clone in myelodysplastic syndrome patients with 5q deletion.
द्वारा: Pellagatti, A, और अन्य
प्रकाशित: (2006)

Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.
द्वारा: Jädersten, M, और अन्य
प्रकाशित: (2009)

Application of classical Hermitian self-orthogonal MDS codes to quantum MDS codes
द्वारा: Jin, Lingfei, और अन्य
प्रकाशित: (2012)

Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.
द्वारा: Pellagatti, A, और अन्य
प्रकाशित: (2007)

Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma
द्वारा: Gooding, S, और अन्य
प्रकाशित: (2020)

Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): a state-of-the-art report on behalf of the International Consortium for MDS (icMDS)
द्वारा: Stahl, M, और अन्य
प्रकाशित: (2023)

New quantum MDS codes
द्वारा: Zhang, Guanghui, और अन्य
प्रकाशित: (2015)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk myelodysplastic syndrome: the Phase 3, randomized, ENHANCE Study
द्वारा: Garcia-Manero, G, और अन्य
प्रकाशित: (2021)

SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS
द्वारा: Malcovati, L, और अन्य
प्रकाशित: (2020)

High-resolution genomic profiling of myelodysplasia (MDS) by microarray comparative genomic hybridization (CGH).
द्वारा: Esoof, N, और अन्य
प्रकाशित: (2006)

Diffusion analysis of EFN-MDS structure
द्वारा: Ibrahim, Subariah
प्रकाशित: (2006)

Diffusion analysis of EFN-MDS structure
द्वारा: Ibrahim, Subariah, और अन्य
प्रकाशित: (2006)

MDS plus data acquisition system
द्वारा: Stillerman, J.A., और अन्य
प्रकाशित: (2015)

Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS.
द्वारा: Zhou, L, और अन्य
प्रकाशित: (2008)

High-resolution genomic profiling of myelodysplasia (MDS) by microarray comparative genomic hybridisation (CGH)
द्वारा: Esoof, N, और अन्य
प्रकाशित: (2005)

Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)
द्वारा: Efficace, F, और अन्य
प्रकाशित: (2024)

Trisomy X and myelodysplastic syndrome (MDS) with eosinophilia
द्वारा: Mohd Tohit, Eusni Rahayu, और अन्य
प्रकाशित: (2012)

Application of constacyclic codes to quantum MDS codes
द्वारा: Chen, Bocong, और अन्य
प्रकाशित: (2015)

A construction of MDS quantum convolutional codes
द्वारा: Zhang, Guanghui, और अन्य
प्रकाशित: (2015)

On linear codes whose hermitian hulls are MDS
द्वारा: Luo, Gaojun, और अन्य
प्रकाशित: (2024)

Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes
द्वारा: Unnikrishnan, A, और अन्य
प्रकाशित: (2017)

Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities.
द्वारा: Dennis, M, और अन्य
प्रकाशित: (2013)

miR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling.
द्वारा: Bhagat, T, और अन्य
प्रकाशित: (2013)

miR-21 mediates hematopoietic suppression in MDS by activating TGF-beta signaling
द्वारा: Bhagat, T, और अन्य
प्रकाशित: (2013)

Gene expression profiling in MDS and AML: potential and future avenues.
द्वारा: Theilgaard-Mönch, K, और अन्य
प्रकाशित: (2011)